Portfolio Companies News
March 18, 2018Strongbridge Biopharma plc Announce...
~ Data Suggest Levoketoconazole, the Isolated 2S,4R Enantiomer of Ketoconazole, Accounts for Essentially All of the Inhibition by Ketoconazole of Cortisol Biosynthesis in Humans ~ ~ Results Presented at ENDO 2018, the Annual Meeting of the Endocrine Society ~ DUBLIN, Ireland and TREVOSE, ... read more
March 15, 2018Nordic Nanovector to Present Precli...
Oslo, Norway, 15 March 2018 Nordic Nanovector ASA (OSE: NANO) announces that it will present a poster reporting the anti-tumour effect of Humalutin® (177Lu-conjugated humanized anti-CD37 antibody, 177Lu-NNV003) in preclinical models of non-Hodgkin’s lymphoma (NHL) at the American Ass... read more
March 15, 2018Onxeo to Present Results of Two Stu...
Paris (France), March 15th, 2018 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and resistant forms of cancer, today announced the presentation of two p... read more
March 15, 2018Targovax ASA: Notice of Annual Gene...
Thursday, March 15, 2018 The Annual General Meeting of Targovax ASA will be held at the Company's offices at Lysaker, on 11 April 2018 at 10:00 CET. Please find the notice including agenda for the General Meeting and appendices attached to this disclosure. The notice will also be sent to... read more
March 14, 2018Onxeo Provides Financial Update
Paris (France), March 14th, 2018 – 8:30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and resistant forms of cancer, today announced that it will record an im... read more
February 07, 2018Q4 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 110 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.